Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

Olaf Stüve, Mariko Kita, Daniel Pelletier, Robert J. Fox, Jerome Stone, Donald E. Goodkin, Scott S. Zamvil

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Mitoxantrone (Novantrone®) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.

Original languageEnglish (US)
JournalMultiple Sclerosis
Volume10
Issue numberSUPPL. 1
StatePublished - Jun 2004

Fingerprint

Chronic Progressive Multiple Sclerosis
Mitoxantrone
North America
Therapeutics
Placebos
Pharmacology
Pharmaceutical Preparations

Keywords

  • Genetics
  • Immunology
  • Magnetic resonance imaging
  • Multiple sclerosis
  • Pathology
  • Primary progressive
  • Therapies

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Stüve, O., Kita, M., Pelletier, D., Fox, R. J., Stone, J., Goodkin, D. E., & Zamvil, S. S. (2004). Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Multiple Sclerosis, 10(SUPPL. 1).

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. / Stüve, Olaf; Kita, Mariko; Pelletier, Daniel; Fox, Robert J.; Stone, Jerome; Goodkin, Donald E.; Zamvil, Scott S.

In: Multiple Sclerosis, Vol. 10, No. SUPPL. 1, 06.2004.

Research output: Contribution to journalArticle

Stüve, O, Kita, M, Pelletier, D, Fox, RJ, Stone, J, Goodkin, DE & Zamvil, SS 2004, 'Mitoxantrone as a potential therapy for primary progressive multiple sclerosis', Multiple Sclerosis, vol. 10, no. SUPPL. 1.
Stüve O, Kita M, Pelletier D, Fox RJ, Stone J, Goodkin DE et al. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Multiple Sclerosis. 2004 Jun;10(SUPPL. 1).
Stüve, Olaf ; Kita, Mariko ; Pelletier, Daniel ; Fox, Robert J. ; Stone, Jerome ; Goodkin, Donald E. ; Zamvil, Scott S. / Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. In: Multiple Sclerosis. 2004 ; Vol. 10, No. SUPPL. 1.
@article{88a642e7d69b4c7da19a8b9bc2892a12,
title = "Mitoxantrone as a potential therapy for primary progressive multiple sclerosis",
abstract = "Mitoxantrone (Novantrone{\circledR}) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.",
keywords = "Genetics, Immunology, Magnetic resonance imaging, Multiple sclerosis, Pathology, Primary progressive, Therapies",
author = "Olaf St{\"u}ve and Mariko Kita and Daniel Pelletier and Fox, {Robert J.} and Jerome Stone and Goodkin, {Donald E.} and Zamvil, {Scott S.}",
year = "2004",
month = "6",
language = "English (US)",
volume = "10",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

AU - Stüve, Olaf

AU - Kita, Mariko

AU - Pelletier, Daniel

AU - Fox, Robert J.

AU - Stone, Jerome

AU - Goodkin, Donald E.

AU - Zamvil, Scott S.

PY - 2004/6

Y1 - 2004/6

N2 - Mitoxantrone (Novantrone®) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.

AB - Mitoxantrone (Novantrone®) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.

KW - Genetics

KW - Immunology

KW - Magnetic resonance imaging

KW - Multiple sclerosis

KW - Pathology

KW - Primary progressive

KW - Therapies

UR - http://www.scopus.com/inward/record.url?scp=3042643912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042643912&partnerID=8YFLogxK

M3 - Article

C2 - 15218811

AN - SCOPUS:3042643912

VL - 10

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - SUPPL. 1

ER -